View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Jazz Pharmaceuticals plc: Key facts and statistics - 2023

A summary company profile, detailing Jazz Pharmaceuticals plc’s business operations and financial highlights.

Jazz Pharmaceuticals plc: Update following upgrade of CFR to Ba2

Our credit view of this issuer reflects its history of maintaining moderate financial leverage and demonstrated commitment to deleveraging.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-tShort Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report...

Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Riccardo Bindi

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...

AMGN AMGEN INC.
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Jazz Pharmaceuticals plc: Update to credit analysis following outlook ...

Our credit view of this issuer reflects its specialty pharmaceutical focus and solid cash flow, tempered by branded and generic competitive pressures facing its sodium oxybate franchise.

JAZZ PHARMACEUTICALS sees an upgrade to Slightly Positive due to a bet...

The general evaluation of JAZZ PHARMACEUTICALS (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 31, 2021, the closing pr...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Jazz Pharmaceuticals plc: Update to credit analysis following GW acqui...

Our credit view of Jazz Pharmaceuticals, reflecting a niche focus, strong growth and solid cash flow, tempered by high financial leverage and revenue concentration.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: May 30, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

HEI HEICO CORPORATION
OXY OCCIDENTAL PETROLEUM CORPORATION
PPG PPG INDUSTRIES INC.
NUE NUCOR CORPORATION
SLB.N SCHLUMBERGER NV
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
SUM SUMMIT MATERIALS INC. CLASS A
AYI ACUITY BRANDS INC.
WOR WORTHINGTON INDUSTRIES INC.
WAT WATERS CORPORATION
VVI VIAD CORP
VALE.N VALE S.A. ADS
TSN TYSON FOODS INC. CLASS A
TSE TRINSEO SA
TS TENARIS S.A. ADS
SXT SENSIENT TECHNOLOGIES CORPORATION
SRI STONERIDGE INC.
SMTC SEMTECH CORPORATION
SLAB SILICON LABORATORIES INC.
SAFM SANDERSON FARMS INC.
RHI ROBERT HALF INTERNATIONAL INC.
PSX PHILLIPS 66
PPC PILGRIM'S PRIDE CORPORATION
PANW PALO ALTO NETWORKS INC.
OLED UNIVERSAL DISPLAY CORPORATION
NUS NU SKIN ENTERPRISES INC. CLASS A
NTGR NETGEAR INC.
MMS MAXIMUS INC.
MKC MCCORMICK & COMPANY INCORPORATED
LPSN LIVEPERSON INC.
LIVN LIVANOVA PLC
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
FANG DIAMONDBACK ENERGY INC.
EOG EOG RESOURCES INC.
DVN DEVON ENERGY CORPORATION
DIS WALT DISNEY COMPANY
CVX CHEVRON CORPORATION
COHR COHERENT INC.
CHEF CHEFS WAREHOUSE HOLDINGS
CEQP CRESTWOOD EQUITY PARTNERS LP
BWA BORGWARNER INC.
AVT AVNET INC.
ALXN ALEXION PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
ACIW ACI WORLDWIDE INC.
ATR APTARGROUP INC.
NOC NORTHROP GRUMMAN CORPORATION
MLM MARTIN MARIETTA MATERIALS INC.
MG/CN MAGNA INTERNATIONAL INC.
NS NUSTAR ENERGY L.P.
MRC MRC GLOBAL INC.
COLM SONAE SGPS SA
DRQ COLUMBIA SPORTSWEAR COMPANY
FSLR DRIL-QUIP INC.
FIRST SOLAR INC.
KFRC IAC/INTERACTIVECORP.
4MG KFORCE INC.
VLO MATCH GROUP INC.
EPD VALERO ENERGY CORPORATION
USFD ENTERPRISE PRODUCTS PARTNERS L.P.
AOS US FOODS HOLDING CORP.
CSCO A. O. SMITH CORPORATION
CNXM CISCO SYSTEMS INC.
DLX CNX MIDSTREAM PARTNERS LP
ABT DELUXE CORPORATION
EAF ABBOTT LABORATORIES
RAMP GRAFTECH INTERNATIONAL
DD LIVERAMP HOLDINGS INC.
OVV DUPONT DE NEMOURS INC.
OVINTIV
INC.
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Karen Andersen
  • Karen Andersen

Morningstar | No-Moat Jazz Pharmaceuticals Remains Reliant on Xyrem Sa...

Jazz Pharmaceuticals found large success with narcolepsy treatment Xyrem and is now transforming into a diversified orphan-focused pharmaceutical firm for life after Xyrem. While the firm still has a way to go, its Exemplary stewardship and successful execution of Xyrem's tricky pricing situation give us confidence in its ability to execute. However, given the uncertainty around the entry of Xyrem generics and Jazz’s lack of diversification in its current portfolio, we believe there is a risk ...

Karen Andersen
  • Karen Andersen

No-Moat Jazz Pharmaceuticals Remains Reliant on Xyrem Sales in Narcole...

We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year. Lead therapy Xyrem for narcolepsy contrib...

Karen Andersen
  • Karen Andersen

Morningstar | Jazz Pharmaceuticals Starts Off 2019 Strong With Growth ...

We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year. Lead therapy Xyrem for narcolepsy contri...

Karen Andersen
  • Karen Andersen

Jazz Pharmaceuticals Starts Off 2019 Strong With Growth in All Major P...

We are maintaining our $153 fair value estimate for no-moat Jazz following the company's first-quarter results, which were mostly in line with our expectations. Total revenue of $508 million met our expectations and represents 14% growth from last year and 7% sequentially. Research and development spend was slightly below our expectations, but we don't plan to change our full-year outlook, as clinical trial costs may ramp up in the back half of the year. Lead therapy Xyrem for narcolepsy contrib...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch